Research Article Details
| Article ID: | A16460 |
| PMID: | 28375109 |
| Source: | Pak J Pharm Sci |
| Title: | Anti hyperlipidemic and hepatoprotective effects of native date fruit variety "Aseel" (Phoenix dactylifera). |
| Abstract: | Diet rich in saturated fats and sugars have been associated with obesity, insulin resistance, hyperlipidemia and fatty liver disease. Especially high serum lipid levels are directly connected to the progression of cardiovascular disorders, which are the leading cause of death all over the world. Date palm fruit (Phoenix dactylifera) is known for numerous health benefits however little information is available about in vivo clinical and preclinical benefits, hence antihyperlipidemic and hepatoprotective potential of native date variety Aseel has been assessed in hyperlipidemia induced albino rats. Forty adult male albino rats were divided into five groups with 8 animals in each group. One group was kept as normal control while remaining four groups were fed high fat high sugar diet for 8 weeks; from this one group was reserved as disease control while two groups as treated which received 300 and 600mg/kg of date fruit suspension. The fourth group served as positive control and received standard drug atorvastatin in the dose of 2.1mg/kg. After 14 days serum lipid profile, hepatic profile and fasting blood sugar were determined for all groups. Fasting blood sugar, cholesterol, triglycerides, LDL and VLDL along with cholesterol- HDL and LDL-HDL ratio were significantly decreased at 300 mg/kg without any increase in liver enzymes as observed in positive control group. Animals received 600 mg/kg also revealed significant decline in fasting blood sugar, triglyceride, VLDL and alkaline phosphatase. Hence present results demonstrate ameliorative role of date fruit in hyperlipidemia and fatty liver however more studies are required to gain insight into the possible mechanism of action and confirmation of these effects on human subjects. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D020 | Atorvastatin | Chemical drug | DB01076 | DPP4 inhibitor; AHR agonist; HDAC2 inhibitor; NR1I3 ligand | Enhance lipid metabolism | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |